clinical trial · NCT06780579

Expanded Access for Bulevirtide

Gilead Sciences·—·approved for marketing

Chronic Hepatitis Delta Virus InfectionBulevirtide

brief summary

The goal of this study is to provide access to bulevirtide (BLV (GS-4438), Hepcludex®) to eligible participants with chronic hepatitis delta virus infection (CHD).

started

—

primary completion

—

completion

—

last updated

Jun 12, 2026

official title

Expanded Access Treatment Protocol for Bulevirtide

full record on clinicaltrials.gov ↗

sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol